Search
BioNTech's Kigali Production Base Secures €95 Million in Financing to Boost mRNA Vaccine Production
2025-10-13 /
Read about 0 minute
Author：小编
On October 13, the European Investment Bank and the European Commission announced that they would provide hybrid financing of up to €95 million to the German biotechnology company BioNTech to support the establishment of an mRNA vaccine production base in Kigali, the capital of Rwanda. The base plans to produce mRNA vaccines targeting diseases such as malaria, tuberculosis, AIDS, and monkeypox (subject to successful research, development, and approval). The financing package includes a €35 million grant from the European Commission and a loan facility of up to €60 million from the European Investment Bank.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
